title: Increased one-year risk of symptomatic venous thromboembolism following total hip replacement: a nationwide cohort study.
abstract: We examined the one-year risk of symptomatic   venous thromboembolism (VTE) following primary total hip replacement   (THR) among Danish patients and a comparison cohort from the general   population. From the Danish Hip Arthroplasty Registry we identified   all primary THRs performed in Denmark between 1995 and 2010 (n =   85 965). In all, 97% of patients undergoing THR received low-molecular-weight   heparin products during hospitalisation. Through the Danish Civil   Registration System we sampled a comparison cohort who had not undergone   THR from the general population (n = 257 895). Among the patients   undergoing THR, the risk of symptomatic VTE was 0.79% between 0   and 90 days after surgery and 0.29% between 91 and 365 days after   surgery. In the comparison cohort the corresponding risks were 0.05%   and 0.12%, respectively. The adjusted relative risks of symptomatic   VTE among patients undergoing THR were 15.84 (95% confidence interval   (CI) 13.12 to 19.12) during the first 90 days after surgery and   2.41 (95% CI 2.04 to 2.85) during 91 to 365 days after surgery,   compared with the comparison cohort. The relative risk of VTE was   elevated irrespective of the gender, age and level of comorbidity   at the time of THR. We concluded that THR was associated with an increased risk of   symptomatic VTE up to one year after surgery compared with the general   population, although the absolute risk is small.
authors.affiliation: Aarhus University Hospital, Department of Clinical Epidemiology, Olof Palmes Allé 43-45, DK-8200 Aarhus N, Denmark. abp@dce.au.dk
authors.forename: A B
authors.initials: AB
authors.lastname: Pedersen
authors.forename: S P
authors.initials: SP
authors.lastname: Johnsen
authors.forename: H T
authors.initials: HT
authors.lastname: Sørensen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D002648:Child; D015331:Cohort Studies; D003718:Denmark / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012306:Risk; D018570:Risk Assessment; D054556:Venous Thromboembolism / Q000453:epidemiology* / Q000209:etiology; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D006493:Heparin